• Skip to primary navigation
  • Skip to main content
  • Skip to footer
  • Skip to investors navigation
Scholar Rock

Scholar Rock

Discovery and Development of Innovative Medicines

  • Careers
  • Newsroom
  • Contact Us
  • Patients & Families
    • Patients & Families
    • Areas of Focus
      • Spinal Muscular Atrophy
    • Patient Stories
    • Clinical Trials
    • Resources
    • Expanded Access

    Learn about our commitment to creating possibilities for those living with serious disease.

    Patients & Families

  • Our Company
    • Our Company
    • Mission & Vision
    • Newsroom
    • Careers
    • Management Team
    • Board of Directors

    Meet Scholar Rock, a biopharmaceutical company committed to improving lives.

    Our Company

  • Our Science
    • Our Science
    • Platform
    • Publications & Posters

    Discover how our breakthrough approach treats complex disease at its biological root.

    Our Science

  • Our Pipeline
    • Our Pipeline
    • Neuromuscular and Obesity
      • Spinal Muscular Atrophy
      • Cardiometabolic Disorders
    • Immuno-Oncology
      • Cancer (solid tumors)
    • Fibrotic Diseases
      • Fibrosis
    • Hematology
      • Anemia
  • Investors & Media
    • Investor Overview
    • Press Releases
      • Archived Press Releases
    • Events & Presentations
    • Corporate Governance
      • Management Team
      • Board of Directors
      • Committee Composition
    • Financials & Filinigs
      • SEC Filings
    • Stock Information
      • Historical Stock Lookup
      • Investment Calculator
      • Analyst Coverage
    • Investor FAQs
    • Contact IR or Media
Home Our Company Board of Directors Akshay Vaishnaw, M.D., Ph.D.
Akshay

Akshay Vaishnaw, M.D., Ph.D.

President, R&D, Scholar Rock

Dr. Akshay Vaishnaw has served as a member of our board of directors since May 2019. Dr. Vaishnaw joined Alnylam Pharmaceuticals in 2006, and currently serves as Chief Innovation Officer and is a member of its Scientific Advisory Board. Prior to Alnylam, he held various positions of increasing responsibility in clinical research and business development at Biogen, Inc., mostly recently Senior Director, Translational Medicine. Dr. Vaishnaw received a BS from University College Cardiff, U.K., an MD from the University of Wales College of Medicine, U.K., and a PhD in molecular immunology from the University of London, U.K. He is a Fellow of the Royal College of Physicians, U.K. Dr. Vaishnaw also serves on the Board of Directors for Editas Medicine Inc., Hemab Therapeutics, and as a Venture Partner at Atlas Venture.

Return to Board of Directors

Footer

Scholar Rock, Inc.
301 Binney Street, 3rd Floor
Cambridge, MA 02142

Phone: 857.259.3860
[email protected]

LinkedIn X, formally Twitter
© 2025 All Rights Reserved
  • Community Guidelines
  • Expanded Access
  • Privacy Policy
  • Terms of Use

We are Scholar Rock.

A biopharmaceutical company dedicated to discovering, developing, and delivering therapies that create new possibilities for patients.

Learn More About Our Pipeline

  • Community Guidelines
  • Expanded Access
  • Privacy Policy
  • Terms of Use
logo
  • Patients & Families
    • Areas of Focus
      • Spinal Muscular Atrophy
    • Patient Stories
    • Clinical Trials
    • Resources
    • Expanded Access
  • Our Company
    • Mission & Vision
    • Newsroom
    • Careers
    • Management Team
    • Board of Directors
    • Partnering
  • Our Science
    • Platform
    • Publications & Posters
  • Our Pipeline
    • Neuromuscular and Obesity
      • Spinal Muscular Atrophy
      • Cardiometabolic Disorders
    • Immuno-Oncology
      • Cancer (solid tumors)
    • Fibrotic Diseases
      • Fibrosis
    • Hematology
      • Anemia
  • Investors & Media
    • Press Releases
      • Archived Press Releases
    • Events & Presentations
    • Corporate Governance
      • Management Team
      • Board of Directors
      • Committee Composition
    • Financials & Filings
      • SEC Filings
    • Stock Information
      • Historical Stock Lookup
      • Investment Calculator
      • Analyst Coverage
    • Investor FAQs
    • Contact IR or Media
  • Careers
  • Newsroom
  • Contact Us

You are now leaving the Scholar Rock website.

This external link is provided for your convenience. Scholar Rock is not responsible for content on external websites.

Continue